This is a single-institution, single-arm, open-label Phase 2 trial evaluating evofosfamide in subjects with M1 CRPC who fail first-line ARSIs. In those progressing after second-line Docetaxel or deemed ineligible to it, the use of alternate ARSI remains the most common line of therapy in our Province, in keeping with recent international recommendations. After baseline molecular imaging (PSMA and fluorodeoxyglucose (FDG) PET/CT), prior to evofosfamide initiation, subjects will be encouraged to undergo biopsy of a dominant lesion: FDG-, PSMA-uptake and/or conventional imaging determined (in order, and according to feasibility). Subjects will then receive the alternate ARSI (i.e., different from the one received in first line) as per current standard practice and Provincial drug plan coverage. Additionally, subjects will receive combinatorial evofosfamide at a dose of 480 mg/m2 intravenously (IV) over 60 minutes on Days 1, 8 and 15 of every 28-day cycle. Therapy will continue until disease progression, unacceptable toxicity as a result of evofosfamide, or subject withdrawal. Assessments during evofosfamide treatment will include history, physical exam, and blood tests at each monthly visit to monitor for toxicity. Response and progression will be evaluated by whole-body PSMA PET/CT scan every 8 weeks (± 3 days) and determined using (PE)RECIST v1.1 criteria. PSA, NE markers (e.g., Serum CHGA, NSE), organ function tests (e.g., liver, kidney) and investigational liquid biopsy samples will be followed every cycle (monthly). FDG PET/CT will be performed at baseline, at 6-10 weeks from the date of signing the informed consent form (ICF), and upon progression, irrespective of treatment discontinuation or initiation of another therapy. Subjects will be followed for survival endpoints following completion of this study treatment until death.

Start Date01 Apr 2025

Sponsor / Collaborator

University Health Network

[+1]

NCT06782555

/ RecruitingPhase 1/2

A Phase 1/2 Immunotherapy Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab in Patients with Advanced Solid Malignancies

The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma virus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN).

Start Date08 Jan 2025

Sponsor / Collaborator

Immunogenesis, Inc.

[+1]

NCT03098160

/ Unknown statusPhase 1

A Phase 1 Immunotherapy Study of Evofosfamide in Combination With Ipilimumab in Patients With Advanced Solid Malignancies

An immunotherapy study combining ipilimumab and evofosfamide for the treatment of patients with confirmed metastatic or locally advanced prostate cancer, metastatic pancreatic cancer, melanoma or human papillomavirus (HPV) negative squamous cell carcinoma of head and neck that have failed to respond to standard therapy, progressed despite standard therapy, for which standard therapy does not offer the potential for increased survival.

Start Date10 May 2017

Sponsor / Collaborator

Threshold Pharmaceuticals, Inc.

[+1]

100 Clinical Results associated with Evofosfamide

100 Translational Medicine associated with Evofosfamide

100 Patents (Medical) associated with Evofosfamide

146

Literatures (Medical) associated with Evofosfamide

01 Nov 2025·INTERNATIONAL JOURNAL OF PHARMACEUTICS

Multifunctional nanoliposome-loaded hypoxia-activated evofosfamide: improving antitumor activity and ferroptosis in pancreatic adenocarcinoma

Article

Author: Yi, Bo ; Sun, Lei ; Chen, Jing ; Zhou, Haiyang

The brief lifetime of reduced O₂ levels and oxygen species during ferroptosis in cancer cell lines undermines the ferroptosis efficacy. Enhancing the effectiveness of real-time created active oxygen species is crucial for pancreatic adenocarcinoma. The Evofosfamide (EFA) encapsulated polydopamine (PD)-iron (Fe) nanoparticles (Fe/PD-EFA) were modified with unsaturated liposomes (Lipo) to address the limitations of conventional ferroptosis therapy. The Lipo@Fe/PD-EFA can interact with H₂O₂ to generate •OH, which subsequently targets Lipo, resulting in the formation of a phospholipid peroxide radical (LOO•) and a radical intermediate (L•) to mitigate the detrimental effects of the •OH. Liposomes facilitate oxygen consumption and augment lipid peroxidation, thereby exacerbating hypoxia at the site of pancreatic cancer. The EFA can be activated by reductase in cancer cell lines under a hypoxic milieu, which diminishes free radicals through the reductase enzyme and disrupts the adjacent biomacromolecules' structure, thereby facilitating the synergistic therapy of chemotherapy and ferroptosis in Panc-1 cells. This study integrates improved ferroptosis with hypoxia-activated chemotherapy to generate an effective and targeted tumoricidal impact, perhaps offering a promising treatment for pancreatic adenocarcinoma (PDAC) in the future.

01 Oct 2025·NANO LETTERS

Spatiotemporally Ultrasound-Activatable Self-Amplifying Biomimetic Liposomes for Imaging-Guided Synergistic Cancer Sonodynamic Chemotherapy

Article

Author: Ji, Xiaojuan ; Zheng, Guangrong ; Liao, Hongchun ; Wang, Yi ; Deng, Dan ; Gong, Ting ; Chen, Jincui ; Sun, Ke ; Yang, Haiyan ; Zhao, Yanbing ; Zhao, Hao ; He, Youqian ; Chen, Xin ; Wang, Zhigang

Overcoming hypoxia and enhancing therapeutic precision remain critical challenges for sonodynamic therapy (SDT) in oncology. Herein, we develop a biomimetic liposomal platform (DiR-VT@cmLipo) coencapsulating the sonosensitizer verteporfin (VP) and hypoxia-activated prodrug evofosfamide (TH302), which synergistically inhibits tumor progression via fluorescence imaging-guided ultrasound-activated spatiotemporally selective sonodynamic-chemotherapy. Engineered with natural membrane components, DiR-VT@cmLipo exhibits prolonged systemic circulation while maintaining precise tumor-specific accumulation after intravenous injection. The therapeutic cascade was precisely initiated through an ultrasound-triggered VP-mediated ROS burst, simultaneously consuming intratumoral oxygen. This creates a self-amplifying hypoxia gradient to promote the activation of cytotoxic payload TH302, enhancing SDT efficacy through synergistic mechanisms. This biomimetic nanoplatform represents an innovative strategy for overcoming microenvironmental limitations in SDT, establishing a paradigm for synergistic tumor microenvironment remodeling and precision-controlled combination therapy. The cascaded self-amplifying activation mechanism and spatiotemporally tumor-selective therapeutic amplification position DiR-VT@cmLipo as a promising candidate for clinical translation in solid tumor management.

01 Jul 2025·BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Design, synthesis, and biological evaluation of hypoxic-activation prodrug TH-302 derivatives

Article

Author: Wang, Shun ; Li, Zhengyi ; Wang, Xin ; Yang, Ke ; Ma, Hongzhao ; Shi, Jing ; Yang, Xingchen

This study aims to design and develop novel and efficient anti-hypoxic cell tumor drugs. Using the TH-302 as lead compound, structural modifications are conducted to synthesize a series of novel derivatives to investigate the structural activity relationship (SAR) against ovarian cancer cell line (SKOV3) and glioblastoma cell line (U87MG) in vitro. The structural modifications mainly include four aspects: changes in substituents on N; changes in isomers; changes in nitro group position; changes in substituting halogens in phosphoramide mustard. The results of CCK-8 assay indicate that the steric hindrance and electronic effects of substituents on N have significant impacts on the activity, while changes in nitro group positions have minimal effects on the activity, and Bromo-phosphoramide mustard exhibits better activity than Chloro-phosphoramide mustard. Compounds 15c and 16d exhibit significantly superior antitumor activity compared to TH-302, with IC₅₀ values of 42 μM and 32 μM for SKOV3 cells, and IC₅₀ values of 47 μM and 41 μM for U87MG cells, respectively.

News (Medical) associated with Evofosfamide

01 Jul 2025

·www.prnewswire.com

ImmunoGenesis Announces the Formation of Scientific Advisory Board

Initial meeting of Scientific Advisory Board (SAB) convened to discuss the first-in-human phase 1a/1b clinical trial of IMGS-001, a dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function designed to treat the many "immune-excluded" cancers that are resistant to existing immunotherapies HOUSTON, July 1, 2025 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies is encouraged by the early performance of IMGS-001 in the ongoing Phase 1a dose escalation study in adult patients with locally advanced or metastatic solid tumors refractory to standard-of-care treatment. To advise on the clinical development strategy for IMGS-001 and other pipeline agents, the company is proud to announce the appointment of a six-member Scientific Advisory Board (SAB) who recently met to review our clinical data and provide input on the upcoming next phase of the IMGS-001 Phase 1a/1b study. "These distinguished members are true leaders in the field of immuno-oncology and come from some of the world's most prestigious cancer centers," said James Barlow, President and CEO of ImmunoGenesis. "I'm honored that the company can collaborate with this esteemed group of scientific and clinical experts whose insights will be instrumental in maximizing the potential of our lead agent to make a meaningful impact in treating some of the most challenging cancers." More details on the newly formed SAB are at the following link: About ImmunoGenesis ImmunoGenesis is a clinical-stage biotech company dedicated to transforming immuno-oncology by targeting key mechanisms of immune resistance. The company's lead product, IMGS-001, is a cytotoxic, dual-specific PD-L1/PD-L2 antibody currently in a Phase 1a/b clinical trial for the treatment of immune-excluded ("cold") tumors, which account for more than half of all cancers. In addition to its lead program, the company has a second clinical asset, IMGS-101 that has the potential to reverse tumor hypoxia, a major immunosuppressive element in solid tumors. The company has additional agents in the pipeline which represent novel approaches to overcome immune resistance in cold tumors. ImmunoGenesis designs therapies to address the pathology of these tumors, overcoming immune exclusion to elicit a robust immune response. For more information, visit . About IMGS-001, a PD-L1/PD-L2 Dual-Specific Inhibitor IMGS-001 is a PD-L1/PD-L2 dual-specific inhibitor with engineered cytotoxic effector function. It is the first molecule to target PD-L2 in addition to PD-L1, potentially shutting down the entire PD-1 pathway and providing a superior blockade compared to other PD-1 or PD-L1 inhibitors. Its engineered effector function enables IMGS-001 to kill immunosuppressive PD-L1- and/or PD-L2-expressing cells present in the tumor microenvironment, providing the potential to overcome immune resistance in immune-excluded tumors. Preclinical data showed that IMGS-001 drove superior survival rates and tumor growth inhibition in head-to-head studies compared to currently available immunotherapies. With its cytotoxic killing function and superior blockade, IMGS-001 may provide a new foundation for combination immuno-oncology therapies. This Phase 1a/b study is being conducted with support from an investment from the Cancer Focus Fund, LP and the Cancer Prevention and Research Institute of Texas (CPRIT) DP200094. Disclosures MD Anderson's relationship with ImmunoGenesis, and all research conducted at MD Anderson related to ImmunoGenesis, has been identified as an institutional financial conflict of interest by MD Anderson's Institutional Conflict of Interest Committee and is managed under an Institutional Conflict of Interest Management and Monitoring Plan. Dr. Curran and Dr. Hong receive compensation as members of the Immunogenesis SAB, and these financial relationships have been disclosed to MD Anderson's Conflict of Interest Committee in accordance with institutional policy. Contact ImmunoGenesis Investors: James Barlow President and CEO [email protected] SOURCE Immunogenesis Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ImmunotherapyPhase 1AACR

06 Mar 2025

·www.prnewswire.com

ImmunoGenesis Doses First Patient in Phase 1/2 Clinical Trial of IMGS-101 in Combination With Balstilimab (anti-PD-1) and Zalifrelimab (anti-CTLA-4) in Relapsed or Refractory Advanced Prostate, Pancreatic, and HPV(-) Head & Neck Tumors

IMGS-101 is the only known reducer of solid tumor hypoxia, offering the potential to enhance the efficacy of immunotherapy HOUSTON, March 6, 2025 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced the first patient has been dosed in the company's Phase 1/2 clinical trial of its hypoxia reversal agent IMGS-101 (evofosfamide) in combination with Balstilimab (anti-PD-1) and Zalifrelimab (anti-CTLA-4) at The University of Texas MD Anderson Cancer Center in Houston, Texas. Tumor hypoxia (low oxygen levels) is an immunosuppressive factor in solid tumors. By reversing hypoxia, IMGS-101 may improve the efficacy of immunotherapies in cancer types that are otherwise resistant to immune-based treatments. Continue Reading ImmunoGenesis The Phase 1/2, open-label, multicenter study (NCT06782555) consists of a dose escalation and expansion portion to evaluate the safety, pharmacokinetics, and anti-tumor activity of IMGS-101 in combination with Balstilimab and Zalifrelimab in adult patients with locally advanced or metastatic castration-resistant prostate cancer (CRPC), pancreatic cancer, and human papillomavirus-(HPV) negative squamous cell carcinoma of the head and neck (SCCHN). The study is being conducted in collaboration with Agenus, a clinical-stage immuno-oncology company developing the checkpoint inhibitors Balstilimab and Zalifrelimab. "Launching this trial represents a significant milestone in our mission to target key mechanisms of immune resistance," said ImmunoGenesis President and CEO James Barlow. "By targeting and reversing hypoxia, we aim to unlock the immune system's full potential and redefine the therapeutic landscape for these cancers with high unmet medical needs." "This trial marks an exciting step forward in addressing one of the key challenges in cancer immunotherapy," said Dr. Charles Schweizer, Senior Vice President of Clinical Development at ImmunoGenesis. "Hypoxia limits T-cell infiltration and suppresses immune responses, especially in prostate, pancreatic, and head and neck cancers. By reversing hypoxia, IMGS-101 may restore T-cell access to tumors, enhancing the effectiveness of checkpoint inhibitors and potentially transforming outcomes in these hard-to-treat cancers." About ImmunoGenesis ImmunoGenesis is a clinical-stage biotech company dedicated to transforming immuno-oncology by targeting key mechanisms of immune resistance. The company's lead product, IMGS-001, is a cytotoxic, dual-specific PD-L1/PD-L2 antibody currently in a phase 1a/b clinical trial for the treatment of immune-excluded ("cold") tumors, which account for more than half of all cancers. In addition to its lead program, the company is developing a number of novel approaches to overcome immune resistance in cold tumors. ImmunoGenesis designs therapies to address the pathology of these tumors, overcoming immune exclusion to elicit a robust immune response. For more information, visit . About IMGS-101 IMGS-101, also known as Evofosfamide, is a 2-nitroimidazole prodrug of the cytotoxin bromo-isophosphoramide mustard (Br-IPM) originally developed as a hypoxia-activated prodrug. ImmunoGenesis' Founder, Dr. Michael A. Curran from MD Anderson, demonstrated in his lab that IMGS-101 has the unique ability to address one of the most significant immunosuppressive barriers by reversing hypoxia. In pre-clinical models and a Phase 1 clinical study, IMGS-101 restored T-cell function and showed early signs of synergizing with checkpoint inhibitors. ImmunoGenesis is developing IMGS-101 as a hypoxia-reversal agent that can condition tumors to respond to checkpoint inhibition. About Balstilimab Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in >900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types. Balstilimab is being developed by Agenus, Inc. About Zalifrelimab Zalifrelimab is a novel, fully human monoclonal immunoglobulin G1 (IgG1) designed to block CTLA-4 (cytotoxic T-lymphocyte associated antigen 4) from interacting with its ligands CD80 and CD86. CTLA-4 is a negative regulator of immune activation that is considered a foundational target within the immuno-oncology market. Zalifrelimab is being developed by Agenus, Inc. Disclosure Dr. Curran's financial relationship with ImmunoGenesis is managed and monitored by the MD Anderson Conflict of Interest Committee. Contact ImmunoGenesis Investors: James Barlow President and CEO [email protected] SOURCE Immunogenesis Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ImmunotherapyPhase 1Clinical Result

13 Feb 2024

·www.globenewswire.com

RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations. “I am delighted to announce the addition of Nipun to the RAPT leadership team and welcome his wealth of experience in small molecule product development and commercial manufacturing,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “Nipun fills an important role as we advance zelnecirnon in late-stage clinical trials for inflammatory diseases and tivumecirnon in oncology indications, executing on our mission to bring promising drug candidates to patients with high unmet needs." Nipun brings over 27 years of extensive biopharmaceutical and drug development experience specializing in successful product development and commercial manufacturing. Most recently he served as Chief Corporate Officer at Astex Pharmaceuticals, Inc., where he oversaw the CMC, program management, legal and finance functions. Prior to Astex Pharmaceuticals, Inc., Nipun was Senior Vice President of Pharmaceutical Development and Manufacturing at Threshold Pharmaceuticals where he led the development of TH-302, a hypoxia activated prodrug developed to treat to multiple cancer types. Earlier in his career, Nipun held various roles encompassing drug delivery-based product development, clinical and commercial supply chain management, regulatory filings and product approvals. Nipun holds a Ph.D. in Pharmaceutical Sciences from the University of Maryland and an MBA from the Wharton School of Business. Nipun added, "I am pleased to join the RAPT leadership team during this exciting period. The company boasts a distinctive and diverse portfolio featuring two internally discovered compounds. Both zelnecirnon and tivumecirnon have demonstrated clinical proof of concept in their respective therapeutic areas, underlining the vast potential to make a positive impact for patients in both inflammatory diseases and oncology. I look forward to contributing to the continued advancement of these promising programs." About RAPT Therapeutics, Inc.RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, zelnecirnon (RPT193) and tivumecirnon (FLX475), each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development. Investor Contact:Sylvia Wheelerswheeler@wheelhouselsa.com Media Contact:Aljanae Reynoldsareynolds@wheelhouselsa.com

Executive Change

100 Deals associated with Evofosfamide

External Link

KEGG	Wiki	ATC	Drug Bank
D10704	Evofosfamide	-	DB06091

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Ductal Adenocarcinoma	Phase 3	United States	Immunogenesis, Inc.	01 Dec 2012
Pancreatic Ductal Adenocarcinoma	Phase 3	Germany	Immunogenesis, Inc.	01 Dec 2012
Pancreatic Cancer	Phase 3	United States	Immunogenesis, Inc.	01 Dec 2012
Metastatic Soft Tissue Sarcoma	Phase 3	United States	Threshold Pharmaceuticals, Inc.	01 Sep 2011
Metastatic Soft Tissue Sarcoma	Phase 3	Austria	Threshold Pharmaceuticals, Inc.	01 Sep 2011
Metastatic Soft Tissue Sarcoma	Phase 3	Belgium	Threshold Pharmaceuticals, Inc.	01 Sep 2011
Metastatic Soft Tissue Sarcoma	Phase 3	Canada	Threshold Pharmaceuticals, Inc.	01 Sep 2011
Metastatic Soft Tissue Sarcoma	Phase 3	Denmark	Threshold Pharmaceuticals, Inc.	01 Sep 2011
Metastatic Soft Tissue Sarcoma	Phase 3	France	Threshold Pharmaceuticals, Inc.	01 Sep 2011
Metastatic Soft Tissue Sarcoma	Phase 3	Germany	Threshold Pharmaceuticals, Inc.	01 Sep 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01497444 (Pubmed \| Invest New Drugs) Manual	Phase 1	Hepatocellular Carcinoma \| Renal Cell Carcinoma First line	18	sorafenib+evofosfamide	rivcistfnz(pmfcvdgysl) = Grade 3 rash(1 pt） wynzoszmim (faxhbdzcts ) View more	Positive	01 Aug 2021
NCT03098160 (Pubmed \| Clin Cancer Res) Manual	Phase 1	Neoplasms	21	Ipilimumab+Evofosfamide	vjuuzvxcdu(voiiaapqmw) = zldwxqsrgd jxaongyfzu (jwyrkgimex ) View more	Positive	01 Jun 2021
Pubmed \| Sci Rep Manual	Phase 2	Recurrent Glioblastoma	33	evofosfamide+Bevacizumab	wxvtwpndlw(lcwqlmaqdx) = tdvounpjjs umacpbiqgp (xidldblnps ) View more	Positive	27 Jan 2021
NCT02402062 (GETNE-1408, CTgov)	Phase 2	Pancreatic neuroendocrine tumour metastatic	17	TH-302+Sunitinib	ulrhnijswj(dszsumpmke) = bvqufhgzuy kjeiyezmbo (gkrvfiudss, zsfutilvfx - kgbebmsfpa) View more	-	27 Jul 2020
NCT02342379 (CTgov)	Phase 2	Glioblastoma	35	TH-302+Bevacizumab	ryucoodjwm = lzpkazvixa zwdiimucoy (smxgnrwcxr, ktptblojbv - tlncmwvcot) View more	-	10 Apr 2020
NCT03098160 (P348, SITC2019)	Phase 1	Advanced Malignant Solid Neoplasm	21	Evofosfamide 400mg/m2 + Ipilimumab 3mg/kg	pwddzquqjr(lyndcpwlfp) = n=16 fntlwrjpyn (fqhzwxqrsv ) View more	Positive	01 Nov 2019
NCT03098160 (P348, SITC2019)	Phase 1	Advanced Malignant Solid Neoplasm	21	Evofosfamide 480mg/m2 + Ipilimumab 3mg/kg		Positive	01 Nov 2019
EUCTR2014-004072-30-ES (SUNEVO, ESMO2019)	Phase 2	Pancreatic neuroendocrine tumour metastatic	17	Sunitinib + Evofosfamide	ltxbxoggxw(vcpfolvjdw) = lkhmxjojhh geyeaimfny (ojftrppgik ) View more	-	30 Sep 2019
NCT01403610 (AT-12, CTgov)	Phase 2	Astrocytoma \| High grade glioma	28	Placebo+TH-302 (Cohort 1)	tgbqokbvmp(zllggtrexv) = urhpljegkv flibtlpael (animhgppcy, cnvnyrmehf - kamvotiigx) View more	-	24 Jul 2019
NCT01403610 (AT-12, CTgov)	Phase 2	Astrocytoma \| High grade glioma	28	TH-302 (Cohort 2)	tgbqokbvmp(zllggtrexv) = rsmaeftmrl flibtlpael (animhgppcy, wltazlytmn - njrdstbavg) View more	-	24 Jul 2019
NCT02402062 (ASCO 12019 \| ASCO 22019) Manual	Phase 2	Pancreatic neuroendocrine tumour metastatic	17	evofosfamide+sunitinib	ykfbfyiydj(aougebptnv) = fzriefgdmn ahbwoatjnj (bwyejrzcic ) View more	Negative	03 Jun 2019
NCT01522872 (Pubmed) Manual	Phase 1/2	Multiple Myeloma	59	dexamethasone+evofosfamide	lllivphjeb(dksqeyfwau) = kcmvpqzklh cmihxjexns (sfowfnbdaz ) View more	Positive	15 Jan 2019
NCT01522872 (Pubmed) Manual	Phase 1/2	Multiple Myeloma	59	dexamethasone+bortezomib+evofosfamide	vahzmnyffp(tioiczoudn) = ugaxmpxaxd fqgwzwomwx (hgngdtcuyh ) View more	Positive	15 Jan 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis